These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15534896)

  • 1. Score tests for dose effect in the presence of non-responders.
    Luo X; Boos DD; Tamura RN
    Stat Med; 2004 Dec; 23(23):3581-91. PubMed ID: 15534896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixture models for continuous data in dose-response studies when some animals are unaffected by treatment.
    Boos DD; Brownie C
    Biometrics; 1991 Dec; 47(4):1489-504. PubMed ID: 1786327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Permutation-based variance component test in generalized linear mixed model with application to multilocus genetic association study.
    Zeng P; Zhao Y; Li H; Wang T; Chen F
    BMC Med Res Methodol; 2015 Apr; 15():37. PubMed ID: 25897803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
    Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
    Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are high initial doses of olanzapine required to reduce agitation associated with schizophrenia?
    Townsend MH; Baier MB
    J Clin Psychopharmacol; 2004 Feb; 24(1):95-7. PubMed ID: 14709956
    [No Abstract]   [Full Text] [Related]  

  • 6. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
    Jones B; Taylor CC; Meehan K
    J Clin Psychiatry; 2001; 62 Suppl 2():22-4. PubMed ID: 11232747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Likelihood ratio testing of variance components in the linear mixed-effects model using restricted maximum likelihood.
    Morrell CH
    Biometrics; 1998 Dec; 54(4):1560-8. PubMed ID: 9883552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Test for interaction between treatment and stratum with ordinal responses.
    Uesaka H
    Biometrics; 1993 Mar; 49(1):123-9. PubMed ID: 8513097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continual reassessment method: a likelihood approach.
    O'Quigley J; Shen LZ
    Biometrics; 1996 Jun; 52(2):673-84. PubMed ID: 8672707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonparametric estimation and testing in a cure model.
    Laska EM; Meisner MJ
    Biometrics; 1992 Dec; 48(4):1223-34. PubMed ID: 1290799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.
    Battaglia J; Houston JP; Ahl J; Meyers AL; Kaiser CJ
    Clin Ther; 2005 Oct; 27(10):1612-8. PubMed ID: 16330297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple test procedures for dose finding.
    Tamhane AC; Hochberg Y; Dunnett CW
    Biometrics; 1996 Mar; 52(1):21-37. PubMed ID: 8934584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing for treatment effect in the presence of regression toward the mean.
    George V; Johnson WD; Shahane A; Nick TG
    Biometrics; 1997 Mar; 53(1):49-59. PubMed ID: 9147603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose response signal detection under model uncertainty.
    Dette H; Titoff S; Volgushev S; Bretz F
    Biometrics; 2015 Dec; 71(4):996-1008. PubMed ID: 26228796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A note on multiple testing procedures in dose finding.
    Bauer P
    Biometrics; 1997 Sep; 53(3):1125-8. PubMed ID: 9333343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating reliability and generalizability from hierarchical biomedical data.
    Molenberghs G; Laenen A; Vangeneugden T
    J Biopharm Stat; 2007; 17(4):595-627. PubMed ID: 17613644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.
    Centorrino F; Meyers AL; Ahl J; Cincotta SL; Zun L; Gulliver AH; Kinon BJ; Houston JP
    Hum Psychopharmacol; 2007 Oct; 22(7):455-62. PubMed ID: 17708578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intramuscular aripiprazole in the control of agitation.
    Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
    J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partitioning to uncover conditions for permutation tests to control multiple testing error rates.
    Calian V; Li D; Hsu JC
    Biom J; 2008 Oct; 50(5):756-66. PubMed ID: 18932135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction approaches to sequentially searching for an optimal dose.
    Shih WJ
    Biometrics; 1989 Jun; 45(2):623-8. PubMed ID: 2669990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.